Abstract 5797
Background
We aimed to describe clinico-pathological features and outcomes of Rahbdomyosarcoma (RMS) in Tunisia.
Methods
We assembled a retrospective cohort of 47 patients aged 18 or older diagnosed with, and treated for RMS at our institute between 1994 and 2013. Patient's characteristics, tumor variables and treatment outcomes were evaluated. Tumors were classified according to the Intergroup RMS Study (IRS) staging.
Results
Median age was 39 and 66% were male. At presentation, 33 had localised disease and 14 metastatic. Metastasis site was lung in 17% of cases. Sixteen patients had node positive disease. Median tumor size was 9 cm. Patients presented with swelling or palpable mass in 63.8% of cases, pain in 17%, exophthalmia in 6.4% and bleeding in 4.3%. Less common clinical presentations were functional impairment, cranial nerve palsies, superior vena cava syndrome and nasal obstruction seen in one case each. Tumor site was extremities in 40.4% of cases, trunk in 23.4%, head and neck in 19.1% and genito-urinary tract in 17%. According to favorable/unfavorable prognostic location, tumor site was unfavorable in 65.9% of cases and favorable in 33.9%. RMS histologic subtype was pleomorphic in 36.2% of patients, embryonic in 25.5%, not mentioned in 23.4%, alveolar in 12.8% and combination of embryonic and alveolar in 2.1%. Among 38 patients who underwent surgery, 40.4% had complete resection (IRS stage I). Chemotherapy was adjuvant in 4 patients, neoadjuvant in 6 and 1st line in 13 with a median number of cycle of 3 in each schedule. Radiotherapy (RT) was adjuvant in 19.1% of cases and symptomatic/palliative in 21.1%. Median dose of adjuvant RT was 55 Gray. Median progression free survival after adjuvant treatment was 4.5 months, 47.1% relapsed locally, 35.3% developed distant metastasis and 17.6% presented local recurrence with distant metastases. Five year overall survival (OS) was 46% for localised RMS and 40% for metastatic disease. Among all studied factors, non operated patients and those under 30 years old had worse OS with p values of 0.005 and 0 respectively.
Conclusions
Adults with RMS have poor prognosis. All patients should therefore undergo multimodality treatment comprising of surgery, radiation, and chemotherapy to achieve better outcomes.
Clinical trial identification
Legal entity responsible for the study
Amel Mezlini.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract